Browse the evidence

All active treatments, including Dapagliflozin 10 mg, Survodutide, Tirzepatide, and higher-dose Semaglutide, improved fibrosis versus placebo.

Practitioners can consider these anti-diabetic agents as effective options for improving liver fibrosis in patients with MASH.

Dose-dependent effects were more prominent for MASH resolution than fibrosis improvement.

Practitioners should consider the dosage of anti-diabetic agents when aiming for MASH resolution.

GLP-1 agonists influence various obesity-related processes including food intake regulation, insulin resistance, and inflammation.

Understanding these mechanisms can help practitioners tailor obesity treatments more effectively.

Metabolic dysfunction associated steatohepatitis (MASH) is a leading cause of chronic liver disease worldwide.

Healthcare providers should recognize MASH as a significant health concern.

MASLD presents extrahepatic manifestations such as cardiovascular disease, type 2 diabetes, and chronic kidney disease.

Clinicians should consider the broader health implications of MASLD beyond liver health.

Obesity, sarcopenia, and heart failure with preserved ejection fraction (HFpEF) are interconnected through the adipokine axis.

Understanding the link between these conditions can guide treatment strategies.

Fecal transplant may have a preventive role in diabetes progression.

Consider the potential of fecal transplants in diabetes prevention strategies.

Increased consumption of simple sugars and fats is directly related to changes in the composition and functions of gut microbiota.

Dietary recommendations should consider the impact of sugar and fat on gut health.

A 6 mg • kg -1 dose of caffeine does not show significant strength improvements compared to a placebo.

Lower doses of caffeine may not be effective for enhancing strength in resistance training.

Statistical methods can separate variability into participant-by-training interaction and within-participant variance.

Using these statistical methods can enhance the accuracy of individual training assessments.

Patients who have undergone significant weight loss are at increased risk of thromboembolic events, particularly after body contouring procedures.

Practitioners should monitor thromboembolic risk in post-weight-loss patients undergoing surgery.

Several factors contribute to obesity-related vasodilator dysfunction, including vascular insulin resistance and lipotoxicity.

Understanding these factors can guide targeted interventions for managing vascular health in obese patients.

Factors such as autonomic dysfunction, left atrial stretch, inflammation, and hormonal imbalances contribute to AF in obese individuals.

Understanding these factors can help in developing targeted interventions for AF in obesity.

MPDA@TZP increased the retention time of TZP in the iWAT of mice and had a more dramatic effect on weight loss and improvement in plasma lipid profiles compared to TZP alone in DIO mice.

Encapsulating tirzepatide may enhance its effectiveness for weight loss in specific adipose tissues.

Endoluminal metabolic and bariatric therapy may be an appealing option for patients ineligible for or averse to bariatric surgery.

Practitioners should consider these therapies for patients who cannot or do not want to undergo traditional surgery.

Future studies investigating the long-term effects of chronic high protein intake on bone tissue health are warranted.

Practitioners should consider the need for ongoing research into the long-term impacts of high protein diets on bone health.

Mitochondrial dysfunction plays a pivotal role in the onset and progression of diabetes.

Understanding mitochondrial dysfunction can guide therapeutic strategies for diabetes management.

Innovative therapeutic strategies are needed to address mitochondrial dysfunction in diabetes.

Practitioners should consider new therapies targeting mitochondrial function in diabetes care.

Different eccentric phase tempos do not produce significant differences in strength and muscle hypertrophy for knee extensors, except for the Vastus Medialis.

Practitioners may not need to vary eccentric tempos for hypertrophy and strength gains in knee extensors, except for targeting the Vastus Medialis.

There were no significant differences in myofibrillar or sarcoplasmic protein concentrations between high and low anabolic responders before or after the 12-week RET program.

Practitioners should note that muscle protein concentrations may not be a reliable indicator of anabolic response to resistance training.

Changes in vastus lateralis muscle thickness did not statistically differ between training programs with different proximities to failure.

Practitioners may consider that varying proximity to failure does not significantly impact muscle thickness gains in trained individuals.

No significant differences were observed in relative volume between the 4-6 RPE and 7-9 RPE groups.

Practitioners can expect similar training volumes to yield comparable results in muscle adaptations.

Changes in post-exercise cell-free DNA (cfDNA) may predict velocity of resistance exercise performance throughout a 96-hour recovery period.

Monitoring cfDNA levels may help trainers assess recovery and performance readiness.

There were no between condition differences for changes in creatine kinase (CK), lactate dehydrogenase (LDH), or delayed onset muscle soreness (DOMS).

Trainers may not need to adjust recovery protocols based on CK, LDH, or DOMS after these exercises.